Skip to main content
NCBI home page
The Texas Heart Institute Journal logoLink to The Texas Heart Institute Journal
. 1995;22(3):211–215.

Antifibrinolytic therapy in cardiac surgery.

R H Chen 1, O H Frazier 1, D A Cooley 1
PMCID: PMC325256  PMID: 7580358

Abstract

Bleeding remains an important complication after repeat and complicated cardiac surgery. Although aprotinin has recently been approved by the Food and Drug Administration for use as an antifibrinolytic agent, many surgeons continue to have concerns about its added cost and potential side effects. We review here the current state of antifibrinolytic therapy for excessive bleeding in cardiothoracic surgery and suggest the use of a single intravenous dose of 10 g of epsilon-aminocaproic acid immediately before cardiopulmonary bypass as a safe, inexpensive, and effective alternative to aprotinin. Further clinical and laboratory studies are needed to confirm or modify this protocol.

Full text

PDF
211

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ALKJAERSIG N., FLETCHER A. P., SHERRY S. The mechanism of clot dissolution by plasmin. J Clin Invest. 1959 Jul;38(7):1086–1095. doi: 10.1172/JCI103885. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Abrams C. S., Ellison N., Budzynski A. Z., Shattil S. J. Direct detection of activated platelets and platelet-derived microparticles in humans. Blood. 1990 Jan 1;75(1):128–138. [PubMed] [Google Scholar]
  3. Adelman B., Michelson A. D., Loscalzo J., Greenberg J., Handin R. I. Plasmin effect on platelet glycoprotein Ib-von Willebrand factor interactions. Blood. 1985 Jan;65(1):32–40. [PubMed] [Google Scholar]
  4. Arom K. V., Emery R. W. Decreased postoperative drainage with addition of epsilon-aminocaproic acid before cardiopulmonary bypass. Ann Thorac Surg. 1994 May;57(5):1108–1113. doi: 10.1016/0003-4975(94)91338-2. [DOI] [PubMed] [Google Scholar]
  5. Blauhut B., Gross C., Necek S., Doran J. E., Späth P., Lundsgaard-Hansen P. Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1991 Jun;101(6):958–967. [PubMed] [Google Scholar]
  6. Blauhut B., Lundsgaard-Hansen P. Reply to invited letter concerning: Aprotinin (J Thorac Cardiovasc Surg 1991; 101:1103-4) J Thorac Cardiovasc Surg. 1992 Feb;103(2):386–387. [PubMed] [Google Scholar]
  7. Bove J. R. Transfusion-associated hepatitis and AIDS. What is the risk? N Engl J Med. 1987 Jul 23;317(4):242–245. doi: 10.1056/NEJM198707233170411. [DOI] [PubMed] [Google Scholar]
  8. Brodsky I., Gill D. N., Lusch C. J. Fibrinolysis in congenital heart disease. Preoperative treatment with epsilon-aminocaproic acid. Am J Clin Pathol. 1969 Jan;51(1):51–57. doi: 10.1093/ajcp/51.1.51. [DOI] [PubMed] [Google Scholar]
  9. Böhrer H., Bach A., Fleischer F., Lang J. Adverse haemodynamic effects of high-dose aprotinin in a paediatric cardiac surgical patient. Anaesthesia. 1990 Oct;45(10):853–854. doi: 10.1111/j.1365-2044.1990.tb14571.x. [DOI] [PubMed] [Google Scholar]
  10. Charytan C., Purtilo D. Glomerular capillary thrombosis and acute renal failure after epsilon-amino caproic acid therapy. N Engl J Med. 1969 May 15;280(20):1102–1104. doi: 10.1056/NEJM196905152802006. [DOI] [PubMed] [Google Scholar]
  11. Cohen N. D., Muñoz A., Reitz B. A., Ness P. K., Frazier O. H., Yawn D. H., Lee H., Blattner W., Donahue J. G., Nelson K. E. Transmission of retroviruses by transfusion of screened blood in patients undergoing cardiac surgery. N Engl J Med. 1989 May 4;320(18):1172–1176. doi: 10.1056/NEJM198905043201803. [DOI] [PubMed] [Google Scholar]
  12. Cosgrove D. M., 3rd, Heric B., Lytle B. W., Taylor P. C., Novoa R., Golding L. A., Stewart R. W., McCarthy P. M., Loop F. D. Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. Ann Thorac Surg. 1992 Dec;54(6):1031–1038. doi: 10.1016/0003-4975(92)90066-d. [DOI] [PubMed] [Google Scholar]
  13. Daily P. O., Lamphere J. A., Dembitsky W. P., Adamson R. M., Dans N. F. Effect of prophylactic epsilon-aminocaproic acid on blood loss and transfusion requirements in patients undergoing first-time coronary artery bypass grafting. A randomized, prospective, double-blind study. J Thorac Cardiovasc Surg. 1994 Jul;108(1):99–108. [PubMed] [Google Scholar]
  14. Dechavanne M., Ffrench M., Pages J., Ffrench P., Boukerche H., Bryon P. A., McGregor J. L. Significant reduction in the binding of a monoclonal antibody (LYP 18) directed against the IIb/IIIa glycoprotein complex to platelets of patients having undergone extracorporeal circulation. Thromb Haemost. 1987 Feb 3;57(1):106–109. [PubMed] [Google Scholar]
  15. DelRossi A. J., Cernaianu A. C., Botros S., Lemole G. M., Moore R. Prophylactic treatment of postperfusion bleeding using EACA. Chest. 1989 Jul;96(1):27–30. doi: 10.1378/chest.96.1.27. [DOI] [PubMed] [Google Scholar]
  16. Dietrich W., Barankay A., Hähnel C., Richter J. A. High-dose aprotinin in cardiac surgery: three years' experience in 1,784 patients. J Cardiothorac Vasc Anesth. 1992 Jun;6(3):324–327. doi: 10.1016/1053-0770(92)90150-6. [DOI] [PubMed] [Google Scholar]
  17. Edmunds L. H., Jr Blood-surface interactions during cardiopulmonary bypass. J Card Surg. 1993 May;8(3):404–410. doi: 10.1111/j.1540-8191.1993.tb00384.x. [DOI] [PubMed] [Google Scholar]
  18. Ferguson T. B., Jr, Muhlbaier L. H., Salai D. L., Wechsler A. S. Coronary bypass grafting after failed elective and failed emergent percutaneous angioplasty. Relative risks of emergent surgical intervention. J Thorac Cardiovasc Surg. 1988 May;95(5):761–772. [PubMed] [Google Scholar]
  19. Ferraris V. A., Ferraris S. P., Lough F. C., Berry W. R. Preoperative aspirin ingestion increases operative blood loss after coronary artery bypass grafting. Ann Thorac Surg. 1988 Jan;45(1):71–74. doi: 10.1016/s0003-4975(10)62401-0. [DOI] [PubMed] [Google Scholar]
  20. Frederiksen M. C., Bowsher D. J., Ruo T. I., Henthorn T. K., Ts'ao C. H., Green D., Atkinson A. J., Jr Kinetics of epsilon-aminocaproic acid distribution, elimination, and antifibrinolytic effects in normal subjects. Clin Pharmacol Ther. 1984 Mar;35(3):387–393. doi: 10.1038/clpt.1984.48. [DOI] [PubMed] [Google Scholar]
  21. Fremes S. E., Wong B. I., Lee E., Mai R., Christakis G. T., McLean R. F., Goldman B. S., Naylor C. D. Metaanalysis of prophylactic drug treatment in the prevention of postoperative bleeding. Ann Thorac Surg. 1994 Dec;58(6):1580–1588. doi: 10.1016/0003-4975(94)91636-5. [DOI] [PubMed] [Google Scholar]
  22. GANS H., KRIVIT W. Problems in hemostasis during openheart surgery. III. Epsilon amino caproic acid as an inhibitor of plasminogen activator activity. Ann Surg. 1962 Feb;155:268–276. doi: 10.1097/00000658-196200000-00017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Harding S. A., Shakoor M. A., Grindon A. J. Platelet support for cardiopulmonary bypass surgery. J Thorac Cardiovasc Surg. 1975 Aug;70(2):350–353. [PubMed] [Google Scholar]
  24. Harker L. A., Malpass T. W., Branson H. E., Hessel E. A., 2nd, Slichter S. J. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective alpha-granule release. Blood. 1980 Nov;56(5):824–834. [PubMed] [Google Scholar]
  25. Havel M., Teufelsbauer H., Knöbl P., Dalmatiner R., Jaksch P., Zwölfer W., Müller M., Vukovich T. Effect of intraoperative aprotinin administration on postoperative bleeding in patients undergoing cardiopulmonary bypass operation. J Thorac Cardiovasc Surg. 1991 Jun;101(6):968–972. [PubMed] [Google Scholar]
  26. Holloway D. S., Summaria L., Sandesara J., Vagher J. P., Alexander J. C., Caprini J. A. Decreased platelet number and function and increased fibrinolysis contribute to postoperative bleeding in cardiopulmonary bypass patients. Thromb Haemost. 1988 Feb 25;59(1):62–67. [PubMed] [Google Scholar]
  27. Horrow J. C., Hlavacek J., Strong M. D., Collier W., Brodsky I., Goldman S. M., Goel I. P. Prophylactic tranexamic acid decreases bleeding after cardiac operations. J Thorac Cardiovasc Surg. 1990 Jan;99(1):70–74. [PubMed] [Google Scholar]
  28. Hoylaerts M., Rijken D. C., Lijnen H. R., Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem. 1982 Mar 25;257(6):2912–2919. [PubMed] [Google Scholar]
  29. Kestin A. S., Valeri C. R., Khuri S. F., Loscalzo J., Ellis P. A., MacGregor H., Birjiniuk V., Ouimet H., Pasche B., Nelson M. J. The platelet function defect of cardiopulmonary bypass. Blood. 1993 Jul 1;82(1):107–117. [PubMed] [Google Scholar]
  30. Kevy S. V., Glickman R. M., Bernhard W. F., Diamond L. K., Gross R. E. The pathogenesis and control of the hemorrhagic defect in open heart surgery. Surg Gynecol Obstet. 1966 Aug;123(2):313–318. [PubMed] [Google Scholar]
  31. Kucuk O., Kwaan H. C., Frederickson J., Wade L., Green D. Increased fibrinolytic activity in patients undergoing cardiopulmonary bypass operation. Am J Hematol. 1986 Nov;23(3):223–229. doi: 10.1002/ajh.2830230306. [DOI] [PubMed] [Google Scholar]
  32. Lambert C. J., Marengo-Rowe A. J., Leveson J. E., Green R. H., Thiele J. P., Geisler G. F., Adam M., Mitchel B. F. The treatment of postperfusion bleeding using epsilon-aminocaproic acid, cryoprecipitate, fresh-frozen plasma, and protamine sulfate. Ann Thorac Surg. 1979 Nov;28(5):440–444. doi: 10.1016/s0003-4975(10)63153-0. [DOI] [PubMed] [Google Scholar]
  33. Levin E. G., Marzec U., Anderson J., Harker L. A. Thrombin stimulates tissue plasminogen activator release from cultured human endothelial cells. J Clin Invest. 1984 Dec;74(6):1988–1995. doi: 10.1172/JCI111620. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Love T. R., Hendren W. G., O'Keefe D. D., Daggett W. M. Transfusion of predonated autologous blood in elective cardiac surgery. Ann Thorac Surg. 1987 May;43(5):508–512. doi: 10.1016/s0003-4975(10)60198-1. [DOI] [PubMed] [Google Scholar]
  35. Lu H., Soria C., Cramer E. M., Soria J., Maclouf J., Perrot J. Y., Li H., Commin P. L., Schumann F., Regnier O. Temperature dependence of plasmin-induced activation or inhibition of human platelets. Blood. 1991 Mar 1;77(5):996–1005. [PubMed] [Google Scholar]
  36. Marx G., Pokar H., Reuter H., Doering V., Tilsner V. The effects of aprotinin on hemostatic function during cardiac surgery. J Cardiothorac Vasc Anesth. 1991 Oct;5(5):467–474. doi: 10.1016/1053-0770(91)90121-9. [DOI] [PubMed] [Google Scholar]
  37. McKenna R., Bachmann F., Whittaker B., Gilson J. R., Weinberg M. The hemostatic mechanism after open-heart surgery. II. Frequency of abnormal platelet functions during and after extracorporeal circulation. J Thorac Cardiovasc Surg. 1975 Aug;70(2):298–308. [PubMed] [Google Scholar]
  38. Mellbring G., Dahlgren S., Wiman B. Plasma fibrinolytic activity in patients undergoing major abdominal surgery. Acta Chir Scand. 1985;151(2):109–114. [PubMed] [Google Scholar]
  39. Midell A. I., Hallman G. L., Bloodwell R. D., Beall A. C., Jr, Yashar J. J., Cooley D. A. Epsilon-aminocaproic acid for bleeding after cardiopulmonary bypass. Ann Thorac Surg. 1971 Jun;11(6):577–582. doi: 10.1016/s0003-4975(10)65076-x. [DOI] [PubMed] [Google Scholar]
  40. Murkin J. M., Lux J., Shannon N. A., Guiraudon G. M., Menkis A. H., McKenzie F. N., Novick R. J. Aprotinin significantly decreases bleeding and transfusion requirements in patients receiving aspirin and undergoing cardiac operations. J Thorac Cardiovasc Surg. 1994 Feb;107(2):554–561. [PubMed] [Google Scholar]
  41. Ovrum E., Am Holen E., Abdelnoor M., Oystese R., Ringdal M. L. Tranexamic acid (Cyklokapron) is not necessary to reduce blood loss after coronary artery bypass operations. J Thorac Cardiovasc Surg. 1993 Jan;105(1):78–83. [PubMed] [Google Scholar]
  42. Ratnoff O. D. Epsilon aminocaproic acid--a dangerous weapon. N Engl J Med. 1969 May 15;280(20):1124–1125. doi: 10.1056/NEJM196905152802011. [DOI] [PubMed] [Google Scholar]
  43. Royston D. High-dose aprotinin therapy: a review of the first five years' experience. J Cardiothorac Vasc Anesth. 1992 Feb;6(1):76–100. doi: 10.1016/1053-0770(91)90052-u. [DOI] [PubMed] [Google Scholar]
  44. Sakariassen K. S., Nievelstein P. F., Coller B. S., Sixma J. J. The role of platelet membrane glycoproteins Ib and IIb-IIIa in platelet adherence to human artery subendothelium. Br J Haematol. 1986 Aug;63(4):681–691. doi: 10.1111/j.1365-2141.1986.tb07552.x. [DOI] [PubMed] [Google Scholar]
  45. Sakata Y., Aoki N. Significance of cross-linking of alpha 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis. J Clin Invest. 1982 Mar;69(3):536–542. doi: 10.1172/JCI110479. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Simon T. L., Akl B. F., Murphy W. Controlled trial of routine administration of platelet concentrates in cardiopulmonary bypass surgery. Ann Thorac Surg. 1984 May;37(5):359–364. doi: 10.1016/s0003-4975(10)60755-2. [DOI] [PubMed] [Google Scholar]
  47. Soslau G., Horrow J., Brodsky I. Effect of tranexamic acid on platelet ADP during extracorporeal circulation. Am J Hematol. 1991 Oct;38(2):113–119. doi: 10.1002/ajh.2830380208. [DOI] [PubMed] [Google Scholar]
  48. Sterns L. P. Lillehei CW: Effect of epsilon aminocaproic acid upon blood loss following open-heart surgery: an analysis of 340 patients. Can J Surg. 1967 Jul;10(3):304–307. [PubMed] [Google Scholar]
  49. Stibbe J., Kluft C., Brommer E. J., Gomes M., de Jong D. S., Nauta J. Enhanced fibrinolytic activity during cardiopulmonary bypass in open-heart surgery in man is caused by extrinsic (tissue-type) plasminogen activator. Eur J Clin Invest. 1984 Oct;14(5):375–382. doi: 10.1111/j.1365-2362.1984.tb01198.x. [DOI] [PubMed] [Google Scholar]
  50. Tanaka K., Takao M., Yada I., Yuasa H., Kusagawa M., Deguchi K. Alterations in coagulation and fibrinolysis associated with cardiopulmonary bypass during open heart surgery. J Cardiothorac Anesth. 1989 Apr;3(2):181–188. doi: 10.1016/s0888-6296(89)92642-2. [DOI] [PubMed] [Google Scholar]
  51. Valeri C. R., Feingold H., Cassidy G., Ragno G., Khuri S., Altschule M. D. Hypothermia-induced reversible platelet dysfunction. Ann Surg. 1987 Feb;205(2):175–181. doi: 10.1097/00000658-198702000-00012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Vander Salm T. J., Ansell J. E., Okike O. N., Marsicano T. H., Lew R., Stephenson W. P., Rooney K. The role of epsilon-aminocaproic acid in reducing bleeding after cardiac operation: a double-blind randomized study. J Thorac Cardiovasc Surg. 1988 Mar;95(3):538–540. [PubMed] [Google Scholar]
  53. Wachtogel Y. T., Musial J., Jenkin B., Niewiarowski S., Edmunds L. H., Jr, Colman R. W. Loss of platelet alpha 2-adrenergic receptors during simulated extracorporeal circulation: prevention with prostaglandin E1. J Lab Clin Med. 1985 May;105(5):601–607. [PubMed] [Google Scholar]
  54. Wenger R. K., Lukasiewicz H., Mikuta B. S., Niewiarowski S., Edmunds L. H., Jr Loss of platelet fibrinogen receptors during clinical cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1989 Feb;97(2):235–239. [PubMed] [Google Scholar]
  55. Westaby S. Aprotinin in perspective. Ann Thorac Surg. 1993 Apr;55(4):1033–1041. doi: 10.1016/0003-4975(93)90149-c. [DOI] [PubMed] [Google Scholar]
  56. Williams E. C. Plasma alpha 2-antiplasmin activity. Role in the evaluation and management of fibrinolytic states and other bleeding disorders. Arch Intern Med. 1989 Aug;149(8):1769–1772. doi: 10.1001/archinte.149.8.1769. [DOI] [PubMed] [Google Scholar]
  57. Wolf P. L. The importance of alpha 2-antiplasmin in the defibrination syndrome. Arch Intern Med. 1989 Aug;149(8):1724–1725. [PubMed] [Google Scholar]
  58. van Oeveren W., Harder M. P., Roozendaal K. J., Eijsman L., Wildevuur C. R. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1990 May;99(5):788–797. [PubMed] [Google Scholar]
  59. van Oeveren W., Jansen N. J., Bidstrup B. P., Royston D., Westaby S., Neuhof H., Wildevuur C. R. Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. Ann Thorac Surg. 1987 Dec;44(6):640–645. doi: 10.1016/s0003-4975(10)62153-4. [DOI] [PubMed] [Google Scholar]

Articles from Texas Heart Institute Journal are provided here courtesy of Texas Heart Institute

RESOURCES